Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas
Open Access
- 1 February 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Clinical Ophthalmology
- Vol. ume 14, 339-346
- https://doi.org/10.2147/opth.s235265
Abstract
Background: To compare iodine-125 ( 125I) with ruthenium-106 ( 106Ru) episcleral plaque radiation therapy in terms of the effectiveness and non-inferiority for choroidal melanoma treatment. Objective: To report the non-inferiority of new made iodine-125 ( 125I) compared with ruthenium-106 ( 106Ru) episcleral plaque radiation. Patients and Methods: A retrospective, non-randomized comparative case series. In this series the patients treated with 125I and 106Ru episcleral plaques for choroidal melanoma between September 2013 and August 2017 at Farabi Hospital are compared. Local control of choroidal melanomas after 125I and 106Ru plaques implantation and vision changes are the main outcome measures. Results: A total of 35 patients were identified ( 125I = 15, 106Ru = 20). No significant difference between two groups in visual acuity, diameter and thickness changes were observed after treatment. Multivariate linear regression (MLR) analysis showed that final diameter was only, independently and significantly, correlated with the pre-treatment diameter of the tumor (β = 0.59, 95% confidence interval [CI]: 0.29, 1.34, P = 0.003). The same MLR analysis for the final thickness and visual acuity, after adjusting for age and sex showed no significant difference between two groups. A single patient treated with 106Ru had local tumor recurrence with no one in the 125I group. No statistical difference in the rate of ocular complications was observed. Conclusion: The treatment with our 125I plaques is as effective as 106Ru plaques in controlling choroidal melanoma tumor and preserving the vision during the two and half year of follow-up. The complication rates are alike. It means that the effectiveness of 125I is not only comparable to 106Ru but also superior when the outcome of the interest is the thickness of the tumors.Keywords
This publication has 42 references indexed in Scilit:
- Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective reviewBrachytherapy, 2015
- A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanomaPractical Radiation Oncology, 2015
- Uveal Melanoma Treated With Iodine-125 Episcleral Plaque: An Analysis of Dose on Disease Control and Visual OutcomesInternational Journal of Radiation Oncology*Biology*Physics, 2014
- Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional ExperienceISRN Ophthalmology, 2014
- The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal MelanomaAmerican Journal of Ophthalmology, 2006
- Quality of Life After Iodine 125 Brachytherapy vs Enucleation for Choroidal MelanomaAmerican Journal of Ophthalmology, 2006
- Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year studyInternational Journal of Radiation Oncology*Biology*Physics, 2002
- The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality FindingsAmerican Journal of Ophthalmology, 2001
- Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapyBritish Journal of Ophthalmology, 2000
- Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanomaOphthalmology, 1999